Target intelligence / Profile preview

Palmitoyl-protein thioesterase 1 (PPT1) (PPT1)

Target
PPT1
Molecular classification
Enzyme, Hydrolase, Thioesterase
01

Overview

Palmitoyl-protein thioesterase 1 (PPT1) is a lysosomal enzyme responsible for removing long-chain fatty acids, such as palmitate, from cysteine residues in proteins during degradation. This process, known as depalmitoylation, is crucial for protein turnover and recycling, particularly in neurons where synaptic vesicle proteins are heavily palmitoylated (UniProt P50897). Mutations in the CLN1 gene lead to a deficiency in PPT1 activity, resulting in the accumulation of palmitoylated proteins as granular osmiophilic deposits (GRODs) within lysosomes (NCBI Gene ID: 1201). This accumulation triggers progressive neurodegeneration, characterized by vision loss, motor decline, seizures, and cognitive impairment, typically presenting in infancy as Infantile Neuronal Ceroid Lipofuscinosis (INCL). Therapeutic strategies currently focus on restoring enzyme function through gene therapy, such as AAV-mediated delivery, or enzyme replacement therapy, as well as exploring small molecules that can bypass the enzyme's function to cleave thioester bonds (PubMed: 31553478).

Other names
CLN1Palmitoyl-protein hydrolase 1Ceroid-lipofuscinosis neuronal protein 1PPT
02

Mechanism of action

Enzyme replacement therapy (restoring catalytic activity), Gene addition therapy (delivering functional CLN1 gene via viral vector), Small molecule depalmitoylation (non-enzymatic cleavage of thioester bonds)

03

Biological functions

Protein depalmitoylationLysosomal degradationLipid metabolismSynaptic vesicle recyclingApoptosis regulation
04

Disease associations

Neuronal ceroid lipofuscinosis 1 (CLN1 disease)Infantile neuronal ceroid lipofuscinosis (INCL)Neurodegenerative disease
05

Safety considerations

Blood-brain barrier penetration for systemic therapiesImmunogenicity against recombinant enzyme or viral vectorsPotential for insertional mutagenesis in gene therapyLimited therapeutic window due to early disease onset
06

Interacting drugs

ABO-202 (AAV9-CLN1 gene therapy)

3 more in the full profile.

07

Biomarkers

PPT1 enzyme activity in leukocytesGranular osmiophilic deposits (GRODs) in skin or blood cellsCLN1 gene mutation statusBrain atrophy via MRINeurofilament light chain (NfL) levels

Beyond the preview

Go deeper on Palmitoyl-protein thioesterase 1 (PPT1) (PPT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Palmitoyl-protein thioesterase 1 (PPT1) (PPT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call